Eicosapentaenoic acid levels predict prognosis of peripheral artery disease caused by aortoiliac artery lesions.


Journal

Nutrition, metabolism, and cardiovascular diseases : NMCD
ISSN: 1590-3729
Titre abrégé: Nutr Metab Cardiovasc Dis
Pays: Netherlands
ID NLM: 9111474

Informations de publication

Date de publication:
04 01 2021
Historique:
received: 08 06 2020
accepted: 10 08 2020
entrez: 27 1 2021
pubmed: 28 1 2021
medline: 3 3 2021
Statut: ppublish

Résumé

Eicosapentaenoic acid (EPA) has been reported to improve clinical outcome of high-risk atherosclerotic patients. We investigated whether endogenous EPA values predict prognosis of peripheral artery disease (PAD) patients. This retrospective study included 166 consecutive patients who had received endovascular therapy (EVT) for PAD caused by aortoiliac artery lesions. Patients were divided into 2 groups using median preoperative EPA value (57 μg/ml): LOW EPA (n = 83) and HIGH EPA (n = 83). We compared differences between the 2 groups in prevalence of major adverse limb events (MALE) which included target lesion revascularization (TLR), non-TLR, and major amputation, and major adverse events (MAE) which included MALE and all cause death. At a median follow-up period of 20 months, MALE had occurred in 24 LOW EPA patients (28.9%) and in 12 HIGH EPA patients (14.5%) (p = 0.04), and MAE had occurred in 41 LOW EPA patients (49.4%) and in 21 HIGH EPA patients (25.3%) (p < 0.01). Kaplan-Meier analysis showed prevalence of MALE and MAE was significantly higher in LOW EPA than in HIGH EPA (long-rank test χ Endogenous EPA value seems to be associated with risk of MALE and MAE after EVT in patients with PAD caused by aortoiliac artery lesions.

Sections du résumé

BACKGROUND AND AIM
Eicosapentaenoic acid (EPA) has been reported to improve clinical outcome of high-risk atherosclerotic patients. We investigated whether endogenous EPA values predict prognosis of peripheral artery disease (PAD) patients.
METHODS AND RESULTS
This retrospective study included 166 consecutive patients who had received endovascular therapy (EVT) for PAD caused by aortoiliac artery lesions. Patients were divided into 2 groups using median preoperative EPA value (57 μg/ml): LOW EPA (n = 83) and HIGH EPA (n = 83). We compared differences between the 2 groups in prevalence of major adverse limb events (MALE) which included target lesion revascularization (TLR), non-TLR, and major amputation, and major adverse events (MAE) which included MALE and all cause death. At a median follow-up period of 20 months, MALE had occurred in 24 LOW EPA patients (28.9%) and in 12 HIGH EPA patients (14.5%) (p = 0.04), and MAE had occurred in 41 LOW EPA patients (49.4%) and in 21 HIGH EPA patients (25.3%) (p < 0.01). Kaplan-Meier analysis showed prevalence of MALE and MAE was significantly higher in LOW EPA than in HIGH EPA (long-rank test χ
CONCLUSIONS
Endogenous EPA value seems to be associated with risk of MALE and MAE after EVT in patients with PAD caused by aortoiliac artery lesions.

Identifiants

pubmed: 33500105
pii: S0939-4753(20)30389-6
doi: 10.1016/j.numecd.2020.08.030
pii:
doi:

Substances chimiques

Biomarkers 0
Eicosapentaenoic Acid AAN7QOV9EA

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

263-268

Informations de copyright

Copyright © 2020 The Italian Diabetes Society, the Italian Society for the Study of Atherosclerosis, the Italian Society of Human Nutrition and the Department of Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The all authors have no conflicts of interest to declare.

Auteurs

Naruhiko Ito (N)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan. Electronic address: nito0516@yahoo.co.jp.

Keiichi Hishikari (K)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Fumiyuki Abe (F)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Yoshinori Kanno (Y)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Munehiro Iiya (M)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Tadashi Murai (T)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Hiroyuki Hikita (H)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Atsushi Takahashi (A)

Cardiovascular Center, Yokosuka Kyosai Hospital, Yokosuka, Japan.

Taishi Yonetsu (T)

Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Tetsuo Sasano (T)

Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH